Navigation Links
Vasogen Announces Sale of Patent Application and Provides Corporate Update
Date:2/2/2009

MISSISSAUGA, ON, Feb. 2 /PRNewswire-FirstCall/ - Vasogen Inc. (NASDAQ: VSGN; TSX:VAS) today announced that it has sold a United States patent application and its related foreign counterparts for US$400,000. This device-based intellectual property has not been used to date in the Celacade System; however, Vasogen has retained rights to this technology for any potential use as it relates to its Celacade System.

The Company today also announced that it continues to advance the process associated with its ongoing strategic review and expects to be in a position to provide a further update to shareholders over the coming weeks. As previously announced, Vasogen has been reviewing various strategic alternatives for the purpose of enhancing shareholder value.

Certain statements in this document constitute "forward-looking statements" within the meaning of the United States Private Securities Litigation Reform Act of 1995 and/or "forward-looking information" under the Securities Act (Ontario). These statements may include, without limitation, plans to complete a sale, merger, acquisition, or other strategic alternative, statements regarding the status of development, or expenditures relating to the Celacade(TM) System or our VP series of drugs including VP015 and VP025, plans to fund our current activities, statements concerning our partnering activities, health regulatory submissions, strategy, future operations, future financial position, future revenues and projected costs. In some cases, you can identify forward-looking statements by terminology such as "may", "will", "should", "expects", "plans", "anticipates", "believes", "estimated", "predicts", "potential", "continue", "intends", "could", or the negative of such terms or other comparable terminology. We made a number of assumptions in the preparation of these forward-looking statements. You should not place undue reliance on our forward-looking statements, which are subject to a multitude of risks and uncertainties that could cause actual results, future circumstances or events to differ materially from those projected. These risks include, but are not limited to, the outcome of our strategic review, securing and maintaining corporate alliances, the need for additional capital and the effect of capital market conditions and other factors, including the current status of our programs, on capital availability, the potential dilutive effects of any financing and other risks detailed from time to time in our public disclosure documents or other filings with the Canadian and U.S. securities commissions or other securities regulatory bodies. Additional risks and uncertainties relating to our Company and our business can be found in the "Risk Factors" section of our Annual Information Form and Form 20-F for the year ended November 30, 2007, as well as in our later public filings, including our Management's Discussion and Analysis for the quarter ended August 31, 2008. The forward-looking statements are made as of the date hereof, and we disclaim any intention and have no obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Vasogen Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Vasogen Complies with NASDAQ Marketplace Rule 4350(c)(1)
2. Vasogen Provides Corporate Update
3. Vasogen Announces Third Quarter 2008 Results
4. Vasogen Announces Second Quarter 2008 Results
5. Vasogen Provides Corporate Update
6. Vasogen to Webcast Presentation at the Rodman & Renshaw 5th Annual Global Healthcare Conference
7. Vasogen Receives NASDAQ Notification Related to Minimum Bid Price
8. Vasogen Announces Implementation of Strategic Restructuring Plan
9. Vasogen Announces First Quarter 2008 Results
10. Vasogen to Webcast its Annual Meeting
11. Vasogen Provides Update on ACCLAIM II Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... Research and Markets has announced the addition of the ... - Global Opportunity Analysis and Industry Forecast, 2014-2022" report to ... ... to reach $15,737 million by 2022 from $6,521 in 2015, growing ... Omic technologies segment accounted for more than half of the ...
(Date:1/19/2017)... , Jan. 19, 2017 /PRNewswire -- WuXi ... device open-access capability and technology platform, today announced ... leading biology focused preclinical drug discovery contract research ... will become a wholly-owned subsidiary of WuXi, and ... competences and providing greater services. The acquisition will ...
(Date:1/19/2017)... ... January 19, 2017 , ... November Research Group, ... biopharmaceutical and medical device manufacturers and regulators, is proud to announce the worldwide ... email client designed to provide product vigilance departments with the flexibility and ease ...
(Date:1/19/2017)... , Jan. 19, 2017 AquaBounty Technologies, ... on enhancing productivity in aquaculture and a majority-owned subsidiary ... that it has completed the listing of its common ... equity subscription from Intrexon. "AquaBounty,s listing on ... will broaden our exposure to the U.S. markets as ...
Breaking Biology Technology:
(Date:12/20/2016)... , Dec. 20, 2016 The rising ... rental and leasing is stoking significant interest in ... frequency technology, Bluetooth low energy (BLE), biometrics and ... the next wave of wireless technologies in the ... system to advanced access systems opens the market ...
(Date:12/16/2016)... , Dec 16, 2016 Research and Markets ... Market - Global Forecast to 2021" report to their offering. ... The biometric ... grow at a CAGR of 14.06% from 2016 to 2021. The ... is projected to reach 854.8 Million by 2021. The growth of ...
(Date:12/15/2016)... 15, 2016 ... Research and Markets has announced the addition of the ... The report forecasts the global military biometrics market to grow ... The report has been prepared based on an in-depth market analysis with ... growth prospects over the coming years. The report also includes a discussion ...
Breaking Biology News(10 mins):